secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pacira BioSciences, Inc. (PCRX)
CIK:        0001396814
Form:       8-K
Filed at:   2022-09-13T23:59:59+00:00
Accession:  0001396814-22-000057
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pacira reports preliminary August net product sales of $59.1M; EXPAREL up 13% YoY
--------------------------------------------------------------------------------

- Total net product sales of $59.1M for August 2022; EXPAREL $46.7M (vs $41.4M in Aug 2021).
- EXPAREL average daily sales were 108% of Aug 2021; 23 selling days vs 22.
- ZILRETTA contributed $9.7M; iovera° $1.5M (up from $0.9M); veterinary sales $1.2M.
- More than 11 million patients have received EXPAREL since launch.
- Company not providing 2022 revenue guidance due to COVID-19 and labor uncertainty.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1396814/000139681422000057/0001396814-22-000057-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1396814/000139681422000057/pcrx-20220913.htm
  HTML page:      https://secwatch.observer/filing/0001396814-22-000057

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer